Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients

Table 1 Clinicohistopathological summary of patients with urothelial carcinoma of bladder

Clinicohistopathological variables	n (%)
Total No. of patients	90 (100)
Age (yr) median, range	60, 38-82
N < 60	41.1)
N ≥ 60	53 (58.9)
Gender
Males	88.9)
Females	10 (11.1)
Hematuria
Present	80)
No information	18 (20)
Smoking/tobacco chewing status
Smokers/tobacco chewers	54.4)
Non-smokers/non-tobacco chewers	30)
No information	14 ( 15.6)
Tumor type
UCB	100)
SCC/others	None
Tumor grade
Low	34.4)
High	59 (65.6)
Tumor stage
NMIBC (pTa-pT1)	53.3)
MIBC (pT2-pT3)	42 (46.7)
Lymph node involvement
N0	91.1)
N1	8 (8.9)
Metastasis
M0	91.1)
M1	8 (8.9)
Type
Primary	56.7)
Recurrent	39 (43.3)
Surgical procedure
TURBT	92.2)
Radical cystectomy	(7.8)
Progression	28.2)
Deaths due to cancer	14 (19.7)

UCB: Urothelial carcinoma of bladder; SCC: Squamous cell carcinoma; TURBT: Transurethral resection of bladder; NMIBC: Non-muscle invasive bladder cancer; MIBC: Muscle invasive bladder cancer.